Currently, there are 63.89M common shares owned by the public and among those 55.55M shares have been available to trade.
The company’s stock has a 5-day price change of 29.58% and 53.44% over the past three months. VRDN shares are trading -13.91% year to date (YTD), with the 12-month market performance up to 3.14% higher. It has a 12-month low price of $10.93 and touched a high of $24.18 over the same period. VRDN has an average intraday trading volume of 1.04 million shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by 25.90%, 27.28%, and 14.11% respectively.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Institutional ownership of Viridian Therapeutics Inc (NASDAQ: VRDN) shares accounts for 96.03% of the company’s 63.89M shares outstanding.
It has a market capitalization of $1.20B and a beta (3y monthly) value of 1.08. The earnings-per-share (ttm) stands at -$4.25. Price movements for the stock have been influenced by the stock’s volatility, which stands at 12.44% over the week and 7.02% over the month.
Earnings per share for the fiscal year are expected to increase by 25.80%, and -8.00% over the next financial year.
Looking at the support for the VRDN, a number of firms have released research notes about the stock. Wolfe Research stated their Outperform rating for the stock in a research note on June 11, 2024, with the firm’s price target at $29. Goldman coverage for the Viridian Therapeutics Inc (VRDN) stock in a research note released on June 06, 2024 offered a Buy rating with a price target of $23. Ladenburg Thalmann was of a view on May 09, 2024 that the stock is Neutral, while B. Riley Securities gave the stock Neutral rating on May 09, 2024, issuing a price target of $25- $20. Credit Suisse on their part issued Outperform rating on June 14, 2023.
